what is glp-1 ra Comprehensive Overview of RAs in Cardiometabolic Care Consensus Recommendations on GLP-1 RA

While SGLT2-i and GLP-1RA may offer additive or synergistic benefits in reducing BP and cardiovascular risk, current guidelines do not support their role as first-line antihypertensive agents or early adjunctive therapies over established agents such as thiazide diuretics, renin-angiotensin system (RAS) inhibitors, or calcium channel blockers (CCBs)

However, the good news is that novel effective treatments to help prevent the progression of DKD in people with type 2 diabetes have been developed over the past decade

Thus, the correlation between GLP-1RAs and tumors has also become a focus of attention in recent years

Follow each products label

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP1 trial extension